SAN

76.89

-0.91%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

SAN

76.89

-0.91%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

SAN

76.89

-0.91%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

SAN

76.89

-0.91%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

SAN

76.89

-0.91%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

59 -1.42

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

58.75

Max

59.05

Põhinäitajad
By Trading Economics
Sissetulek	-33M 9.5M
Müük	-66M 152M
P/E Sektori keskmine	24.576 49.701
Aktsiakasum	0.185
Kasumimarginaal	6.216
Töötajad	1,950
EBITDA	-45M 18M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+24.64% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-1.1B 3B
Eelmine avamishind	60.42
Eelmine sulgemishind	59

Uudiste sentiment

By Acuity

50%

151 / 345 Pingereas Healthcare

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24. mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24. mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24. mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24. mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24. mai 2026, 22:26 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24. mai 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24. mai 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24. mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24. mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23. mai 2026, 08:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

23. mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. mai 2026, 21:10 UTC

Tulu

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. mai 2026, 19:47 UTC

Tulu

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22. mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22. mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22. mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22. mai 2026, 18:35 UTC

Omandamised, ülevõtmised, äriostud

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22. mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22. mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

24.64% tõus

12 kuu keskmine prognoos

Keskmine 73.6 EUR 24.64%

Kõrge 83 EUR

Madal 64.2 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.